About Zafgen (NASDAQ:ZFGN)
Zafgen, Inc., a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders. It also develops ZGN-1258, a MetAP2 inhibitor for treatment of PWS. Zafgen, Inc. was founded in 2005 and is headquartered in Boston, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Trailing P/E Ratio-3.47
Forward P/E Ratio-3.07
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Book Value$2.85 per share
Price / Book2.37
EPS (Most Recent Fiscal Year)($1.90)
Return on Equity-55.08%
Return on Assets-48.40%
Zafgen (NASDAQ:ZFGN) Frequently Asked Questions
What is Zafgen's stock symbol?
Zafgen trades on the NASDAQ under the ticker symbol "ZFGN."
How were Zafgen's earnings last quarter?
Zafgen (NASDAQ:ZFGN) posted its quarterly earnings data on Tuesday, March, 6th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.57) by $0.09. View Zafgen's Earnings History.
When is Zafgen's next earnings date?
What price target have analysts set for ZFGN?
1 analysts have issued 12-month price objectives for Zafgen's shares. Their forecasts range from $20.00 to $20.00. On average, they expect Zafgen's stock price to reach $20.00 in the next year. View Analyst Ratings for Zafgen.
Who are some of Zafgen's key competitors?
Some companies that are related to Zafgen include GTX (GTXI), Dermira (DERM), Clearside Biomedical (CLSD), Strongbridge Biopharma (SBBP), Paratek Pharmaceuticals (PRTK), Merus (MRUS), Kadmon (KDMN), Catalyst Biosciences (CBIO), Durect (DRRX), Seres Therapeutics (MCRB), Celyad (CYAD), AVEO Pharmaceuticals (AVEO), BioSpecifics Technologies (BSTC), Zymeworks (ZYME), Arbutus Biopharma (ABUS), Aquinox Pharmaceuticals (AQXP), Avadel Pharmaceuticals (AVDL) and Savara (SVRA).
Who are Zafgen's key executives?
Zafgen's management team includes the folowing people:
- Dr. Thomas E. Hughes, Pres, Chief Scientific Officer & Director (Age 58)
- Ms. Patricia L. Allen CPA, Chief Financial Officer (Age 56)
- Dr. Dennis D. Kim M.D., MBA, Chief Medical Officer (Age 48)
- Mr. Jeffrey S. Hatfield, CEO & Director (Age 60)
- Dr. James E. Vath Ph.D., Head of Discovery and Devel. (Age 57)
Has Zafgen been receiving favorable news coverage?
News articles about ZFGN stock have trended somewhat positive this week, Accern reports. The research firm identifies negative and positive media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Zafgen earned a daily sentiment score of 0.03 on Accern's scale. They also gave news articles about the biopharmaceutical company an impact score of 45.70 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.
How do I buy shares of Zafgen?
Shares of ZFGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Zafgen's stock price today?
One share of ZFGN stock can currently be purchased for approximately $6.59.
How big of a company is Zafgen?
Zafgen has a market capitalization of $188.50 million. The biopharmaceutical company earns $-52,020,000.00 in net income (profit) each year or ($1.90) on an earnings per share basis. Zafgen employs 35 workers across the globe.
How can I contact Zafgen?
Zafgen's mailing address is 175 PORTLAND STREET 4TH FLOOR, BOSTON MA, 02114. The biopharmaceutical company can be reached via phone at 617-622-4003 or via email at [email protected]
MarketBeat Community Rating for Zafgen (ZFGN)MarketBeat's community ratings are surveys of what our community members think about Zafgen and other stocks. Vote "Outperform" if you believe ZFGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZFGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
Zafgen (NASDAQ:ZFGN) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Zafgen (NASDAQ ZFGN) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 21.20%
Institutional Ownership Percentage: 52.18%
Zafgen (NASDAQ ZFGN) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|3/7/2018||Thomas E. Hughes||Insider||Sell||5,000||$10.00||$50,000.00|| |
|10/13/2017||Frances K Heller||Director||Buy||10,000||$3.90||$39,000.00|| |
|7/11/2017||Dennis D Kim||Insider||Buy||10,000||$3.39||$33,900.00||21,443|| |
|5/11/2017||Dennis D. Kim||Insider||Buy||10,000||$4.40||$44,000.00|| |
|12/19/2016||Frances K Heller||Director||Buy||10,000||$3.23||$32,300.00||30,000|| |
|11/15/2016||Frances K Heller||Director||Buy||10,000||$3.54||$35,400.00||20,000|| |
|8/29/2016||Thomas E Hughes||Insider||Buy||10,000||$3.00||$30,000.00||63,936|| |
|7/26/2016||Patricia L. Allen||CFO||Buy||16,000||$3.12||$49,920.00|| |
|7/22/2016||Frances K Heller||Director||Buy||10,000||$2.99||$29,900.00||10,000|| |
|7/22/2016||Thomas E. Hughes||Insider||Buy||5,000||$3.02||$15,100.00|| |
|2/12/2016||James E Flynn||Insider||Buy||64,545||$6.25||$403,406.25|| |
|2/11/2016||James E Flynn||Insider||Buy||267,493||$6.02||$1,610,307.86|| |
|9/24/2015||Kevin P Starr||Director||Sell||136,579||$43.90||$5,995,818.10||370,323|| |
|9/18/2015||Avi Y Goldberg||Director||Sell||5,000||$45.00||$225,000.00||53,734|| |
|9/18/2015||Thomas E. Hughes||CEO||Sell||45,626||$42.53||$1,940,473.78||820|| |
|9/17/2015||Dennis D. Kim||insider||Sell||39,407||$40.00||$1,576,280.00|| |
|6/10/2015||Avi Y Goldberg||Director||Sell||3,000||$35.00||$105,000.00|| |
|6/1/2015||Avi Y Goldberg||Director||Sell||2,000||$32.23||$64,460.00|| |
|6/19/2014||Alicia Secor||Insider||Buy||4,000||$20.00||$80,000.00|| |
Zafgen (NASDAQ ZFGN) News Headlines
|ValuEngine Downgrades Zafgen (ZFGN) to Strong Sell|
www.americanbankingnews.com - April 21 at 7:06 AM
|Zafgen (ZFGN) Rating Increased to Sell at ValuEngine|
www.americanbankingnews.com - April 12 at 10:47 AM
| Analysts Expect Zafgen (ZFGN) to Announce -$0.53 EPS|
www.americanbankingnews.com - April 10 at 5:22 AM
|ValuEngine Lowers Zafgen (ZFGN) to Strong Sell|
www.americanbankingnews.com - April 7 at 8:19 PM
| Analysts Anticipate Zafgen Inc (ZFGN) to Post -$0.53 EPS|
www.americanbankingnews.com - March 24 at 5:24 AM
|Zafgen (ZFGN) Presents At 38th Annual Cowen And Company Healthcare Conference - Slideshow|
seekingalpha.com - March 15 at 5:39 PM
|Zafgen (ZFGN) Downgraded by Zacks Investment Research to Hold|
www.americanbankingnews.com - March 9 at 9:02 PM
|Insider Selling: Zafgen Inc (ZFGN) Insider Sells 5,000 Shares of Stock|
www.americanbankingnews.com - March 9 at 7:15 PM
|Zafgen Inc to Post Q2 2018 Earnings of ($0.54) Per Share, Leerink Swann Forecasts (ZFGN)|
www.americanbankingnews.com - March 9 at 8:04 AM
|Here's Why Zafgen Inc Rose as Much as 21.1% Today|
finance.yahoo.com - March 7 at 5:58 PM
|Zafgen to Present at Cowen 38th Annual Health Care Conference|
finance.yahoo.com - March 7 at 5:58 PM
|Zafgen (ZFGN) Raised to Buy at Zacks Investment Research|
www.americanbankingnews.com - March 7 at 3:08 PM
|Zafgen (ZFGN) Rating Reiterated by JMP Securities|
www.americanbankingnews.com - March 7 at 1:17 PM
|Zafgen (ZFGN) Issues Earnings Results|
www.americanbankingnews.com - March 7 at 7:54 AM
|Zafgen Inc (ZFGN) Expected to Announce Earnings of -$0.59 Per Share|
www.americanbankingnews.com - March 7 at 1:16 AM
|BRIEF-Zafgen Reports Q4 Loss Per Share $0.48|
www.reuters.com - March 6 at 5:20 PM
|Zafgen Reports Fourth Quarter and Full Year 2017 Financial Results; Announces Positive Interim Data from Ongoing ZGN-1061 Phase 2 Proof-of-Concept Trial in Patients with Type 2 Diabetes|
finance.yahoo.com - March 6 at 5:20 PM
|Royce & Associates LP Grows Position in Zafgen Inc (ZFGN)|
www.americanbankingnews.com - March 6 at 10:52 AM
|AWM Investment Company Inc. Acquires Shares of 400,264 Zafgen Inc (ZFGN)|
www.americanbankingnews.com - March 6 at 4:46 AM
|Leerink Swann Weighs in on Zafgen Inc's FY2019 Earnings (ZFGN)|
www.americanbankingnews.com - March 5 at 7:56 AM
|Acer Therapeutics (ACER) & Zafgen (ZFGN) Critical Contrast|
www.americanbankingnews.com - March 4 at 9:15 PM
|Zafgen to Host Conference Call to Discuss Fourth Quarter and Full Year 2017 Financial Results - GlobeNewswire (press release)|
globenewswire.com - March 3 at 8:42 AM
|Equities Analysts Set Expectations for Zafgen Inc's Q1 2018 Earnings (ZFGN)|
www.americanbankingnews.com - March 2 at 8:06 AM
|Zafgen to Host Conference Call to Discuss Fourth Quarter and Full Year 2017 Financial Results|
finance.yahoo.com - March 1 at 5:28 PM
|Zafgen (ZFGN) Set to Announce Earnings on Wednesday|
www.americanbankingnews.com - February 28 at 1:58 AM
| Brokerages Anticipate Zafgen Inc (ZFGN) to Announce -$0.59 Earnings Per Share|
www.americanbankingnews.com - February 18 at 12:08 PM
|Zafgen (ZFGN) Presents At Leerink Partners 7th Annual Global Healthcare Conference - Slideshow|
seekingalpha.com - February 15 at 5:02 PM
|Zafgen to Present at the Leerink Partners 7th Annual Global Healthcare Conference|
finance.yahoo.com - February 9 at 9:38 AM
|Zafgen (ZFGN) Raised to Sell at ValuEngine|
www.americanbankingnews.com - February 4 at 6:52 AM
|Zymeworks (ZYME) and Zafgen (ZFGN) Financial Contrast|
www.americanbankingnews.com - January 17 at 9:14 PM
|Zafgen (ZFGN) Downgraded to "Hold" at Zacks Investment Research|
www.americanbankingnews.com - January 13 at 4:08 PM
|Blog Exposure - Zafgen Reports Strong Clinical Progress and Updates Outlook|
finance.yahoo.com - January 8 at 10:43 AM
|Zafgen (ZFGN) Announces Strong Clinical Progress and Updates Outlook for 2018|
www.streetinsider.com - January 6 at 10:32 AM
|BRIEF-Zafgen Says Co Entered Into Loan And Security Agreement Providing For Term Loan With Principal Amount Of $20 Mln|
www.reuters.com - January 6 at 10:32 AM
|Zafgen Reports Strong Clinical Progress and Updates Outlook for 2018 |
finance.yahoo.com - January 5 at 10:48 AM
|-$0.59 Earnings Per Share Expected for Zafgen Inc (ZFGN) This Quarter|
www.americanbankingnews.com - December 29 at 3:22 PM
|Zafgen, Inc. (ZFGN) Receives Average Rating of "Hold" from Analysts|
www.americanbankingnews.com - December 15 at 3:54 PM
|-$0.59 EPS Expected for Zafgen, Inc. (ZFGN) This Quarter|
www.americanbankingnews.com - December 12 at 11:36 AM
|Zafgen, Inc. (ZFGN) Expected to Announce Earnings of -$0.59 Per Share|
www.americanbankingnews.com - November 24 at 1:18 PM
|Zafgen, Inc. (ZFGN) Receives Average Recommendation of "Hold" from Analysts|
www.americanbankingnews.com - November 20 at 3:46 PM
|Zacks Investment Research Upgrades Zafgen, Inc. (ZFGN) to "Buy"|
www.americanbankingnews.com - November 11 at 10:22 AM
|Leerink Swann Comments on Zafgen, Inc.'s FY2017 Earnings (ZFGN)|
www.americanbankingnews.com - November 10 at 12:26 PM
|Zafgen, Inc. (ZFGN) Announces Quarterly Earnings Results, Beats Expectations By $0.12 EPS|
www.americanbankingnews.com - November 8 at 7:11 PM
|Zafgen Reports Third Quarter 2017 Financial Results|
finance.yahoo.com - November 7 at 9:28 PM
|Zafgen reports 3Q loss|
finance.yahoo.com - November 7 at 9:28 PM
|Head to Head Contrast: Zafgen (ZFGN) & Its Rivals|
www.americanbankingnews.com - November 1 at 3:12 AM
|Zafgen, Inc. (ZFGN) Set to Announce Quarterly Earnings on Tuesday|
www.americanbankingnews.com - October 31 at 8:52 AM
|Financial Contrast: Zafgen (ZFGN) versus Its Competitors|
www.americanbankingnews.com - October 30 at 11:40 AM
|Zafgen Inc (ZFGN) Receives Average Rating of "Hold" from Brokerages|
www.americanbankingnews.com - October 26 at 5:48 PM
|Zafgen, Inc. (ZFGN) Director Acquires $39,000.00 in Stock|
www.americanbankingnews.com - October 17 at 8:18 PM
Zafgen (NASDAQ:ZFGN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Zafgen (NASDAQ:ZFGN) Income Statement, Balance Sheet and Cash Flow Statement
Zafgen (NASDAQ ZFGN) Stock Chart for Monday, April, 23, 2018